Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
| Country | United States |
| Founded | 1888 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 115,000 |
| CEO | Robert Ford |
Contact Details
Address: 100 Abbott Park Road Abbott Park, Illinois 60064-6400 United States | |
| Phone | 224 667 6100 |
| Website | abbott.com |
Stock Details
| Ticker Symbol | ABT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000001800 |
| CUSIP Number | 002824100 |
| ISIN Number | US0028241000 |
| Employer ID | 36-0698440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert B. Ford | Chairman, President and Chief Executive Officer |
| Philip P. Boudreau | Chief Financial Officer and Executive Vice President of Finance |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals and Nutritional Products |
| Lisa D. Earnhardt | Executive Vice President and Group President of Medical Devices |
| Sabina Ewing | Senior Vice President of Business and Technology Services and Chief Information Officer |
| Michael Comilla | Vice President of Investor Relations. |
| Erica L. Battaglia | Vice President and Chief Ethics and Compliance Officer |
| Elizabeth Cushman | Executive Vice President, General Counsel and Secretary |
| Melissa Brotz | Senior Vice President of Global Marketing and External Affairs |
| Mary K. Moreland | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 424B5 | Filing |
| Feb 24, 2026 | FWP | Free Writing Prospectus |
| Feb 23, 2026 | 424B3 | Prospectus |
| Feb 23, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 10-K | Annual Report |
| Jan 22, 2026 | 8-K | Current Report |
| Dec 12, 2025 | 8-K | Current Report |
| Dec 3, 2025 | SCHEDULE 13G/A | Filing |
| Nov 25, 2025 | 144 | Filing |